Diffuse large b-cell lymphoma stage 1 group a is generally not serious and has a 5-year survival rate of 90% or more. The specifics should be based on a combination of age, gender, presence of symptoms, and treatment outcome. Diffuse large B-cell lymphoma can achieve disease remission in more than 70% of patients after multiple cycles of systemic chemotherapy, but ultimately only 50% to 60% of patients achieve long-term disease-free survival. Specific drugs include cyclophosphamide, vincristine, and azulpiride. In recent years, the use of newer drugs such as anti-CD20 monoclonal antibodies has led to a significant improvement in patient prognosis. The 5-year survival rate of patients with stage 1 and stage 2 diffuse large B-cell lymphoma is above 90%. The prognosis of patients with systemic symptoms is worse than that of those without systemic symptoms, and the prognosis of the elderly and children is worse than that of young and middle-aged people; the prognosis of women is better than that of male patients. Therefore, it should be treated differently and analyzed on a case-by-case basis. It is recommended that if you suffer from the above diseases, go to the hospital in time to receive regular treatment under the guidance of a physician, so as to avoid delaying the condition.